+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Myasthenia Gravis Treatment Market by Treatment Class (Acetylcholinesterase Inhibitors, Immunosuppressants, Intravenous Immunoglobulin), Administration Route (Intravenous, Oral, Subcutaneous), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Myasthenia Gravis Treatment Market by Treatment Class (Acetylcholinesterase Inhibitors, Immunosuppressants, Intravenous Immunoglobulin), Administration Route (Intravenous, Oral, Subcutaneous), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Myasthenia Gravis Treatment Market by Treatment Class (Acetylcholinesterase Inhibitors, Immunosuppressants, Intravenous Immunoglobulin), Administration Route (Intravenous, Oral, Subcutaneous), Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674103
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Myasthenia Gravis Treatment Market is evolving rapidly, shaped by advanced therapies and emerging care models. Senior stakeholders now require actionable intelligence to respond to shifting clinical, regulatory, and operational priorities. This report provides a data-driven overview, synthesizing disruptive trends and strategic insights tailored for leaders charting next-generation growth and partnership opportunities.

Market Snapshot of the Myasthenia Gravis Treatment Market

The Myasthenia Gravis Treatment Market grew from USD 2.00 billion in 2024 to USD 2.11 billion in 2025. It is expected to continue growing at a CAGR of 5.48%, reaching USD 2.76 billion by 2030. This expansion reflects increased demand for both traditional and innovative therapies, adoption of value-based care, and realignment of supply chain strategies. Progressive clinical approaches and digital care integration are driving stakeholders to reassess operational priorities and long-term investments. Key market growth is being driven by novel monoclonal antibodies, evolving reimbursement models, and expanding geographic uptake.

Scope & Segmentation

This research delivers a comprehensive analysis of the Myasthenia Gravis Treatment Market across all major segments, regions, and key players:

  • Treatment Class: Acetylcholinesterase inhibitors, immunosuppressants (including corticosteroids, azathioprine, cyclosporine, mycophenolate mofetil), intravenous immunoglobulin, monoclonal antibodies (eculizumab, ravulizumab, rituximab), plasma exchange
  • Administration Route: Intravenous, oral, subcutaneous
  • Distribution Channel: Hospital pharmacies, online pharmacies, retail pharmacies
  • End User: Clinics, home care, hospitals
  • Region: Americas (United States including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Notable Companies: Alexion Pharmaceuticals, argenx SE, UCB S.A., Takeda, Sanofi, Johnson & Johnson, Pfizer, Novartis, CSL Limited, Roche

Key Takeaways: Strategic Insights for Decision-Makers

  • Stakeholders are prioritizing the adoption of precision immunomodulation, leveraging monoclonal antibodies and biomarker-led treatment to advance personalized care pathways.
  • Digital health solutions, including telemedicine platforms and remote monitoring, are enabling earlier intervention and multidisciplinary collaboration across care settings.
  • Geographic trends highlight varying paces of adoption, with the Americas leading in clinical innovation, and regions such as Asia-Pacific accelerating access through local production and digital infrastructure investment.
  • Integration of value-based agreements and real-world evidence programs is reshaping how payers, providers, and manufacturers justify therapeutic investments and market access.
  • Mergers, acquisitions, and partnerships are consolidating capabilities from research to distribution, enabling more agile responses to market disruptions and regulatory changes.

Assessing Tariff Impact on the Myasthenia Gravis Treatment Market

Revised US tariff regulations have introduced volatility in sourcing raw materials essential to biologic and immunoglobulin-based therapies. This has intensified efforts by manufacturers to strengthen domestic production capacity and diversify supplier networks to minimize future disruption. These shifts are elevating operational risk planning across supply chains and prompting payer–provider dialogues on equitable cost management. The resulting adaptability ensures continuity in patient access while safeguarding against financial and logistical constraints.

Methodology & Data Sources for Market Insights

Findings derive from triangulated secondary research—including peer-reviewed journals, regulatory filings, industry databases, and clinical trial data—augmented by primary interviews with neurologists, pharmacologists, and healthcare administrators. Rigorous content analysis and benchmarking support the identification of emerging trends and opportunities while maintaining high standards of data integrity throughout.

Why This Report Matters

  • Enables senior executives to benchmark current therapeutic approaches and pivot strategies in response to disruptive innovation.
  • Provides an evidence-based foundation for investment, partnership decisions, and risk mitigation across distribution and supply chain operations.
  • Supports payer and provider stakeholders in evaluating cost-effectiveness and patient-centric models within an evolving reimbursement environment.

Conclusion

This research offers a strategic blueprint for navigating the evolving Myasthenia Gravis treatment landscape. Stakeholders can utilize these insights to inform commercial, clinical, and operational decisions in a market defined by technological, regulatory, and stakeholder transformation.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of neonatal Fc receptor inhibitors like efgartigimod into early-line treatment algorithms for generalized myasthenia gravis patients
5.2. Rising demand for complement C5 inhibitors driven by favorable clinical trial results in refractory generalized myasthenia gravis populations
5.3. Emergence of bispecific T cell engager therapies offering targeted immunomodulation in acetylcholine receptor positive myasthenia gravis
5.4. Development of subcutaneous immunoglobulin formulations enhancing patient adherence and quality of life in chronic myasthenia gravis management
5.5. Expansion of telehealth monitoring programs to facilitate remote symptom tracking and individualized treatment adjustments in MG patients
5.6. Increasing industry investment in novel biomarkers for precise disease severity assessment and personalized therapy selection in myasthenia gravis
5.7. Growing proliferation of biosimilar immunoglobulin products challenging branded intravenous therapies and influencing market pricing dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Myasthenia Gravis Treatment Market, by Treatment Class
8.1. Introduction
8.2. Acetylcholinesterase Inhibitors
8.3. Immunosuppressants
8.3.1. Corticosteroids
8.3.2. Nonsteroidal Immunosuppressants
8.3.2.1. Azathioprine
8.3.2.2. Cyclosporine
8.3.2.3. Mycophenolate Mofetil
8.4. Intravenous Immunoglobulin
8.5. Monoclonal Antibodies
8.5.1. Eculizumab
8.5.2. Ravulizumab
8.5.3. Rituximab
8.6. Plasma Exchange
9. Myasthenia Gravis Treatment Market, by Administration Route
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Myasthenia Gravis Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Myasthenia Gravis Treatment Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care
11.4. Hospitals
12. Americas Myasthenia Gravis Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Myasthenia Gravis Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Myasthenia Gravis Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Alexion Pharmaceuticals, Inc.
15.3.2. argenx SE
15.3.3. UCB S.A.
15.3.4. Takeda Pharmaceutical Company Limited
15.3.5. Sanofi S.A.
15.3.6. Johnson & Johnson
15.3.7. Pfizer Inc.
15.3.8. Novartis AG
15.3.9. CSL Limited
15.3.10. Roche Holding AG
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. MYASTHENIA GRAVIS TREATMENT MARKET: RESEARCHAI
FIGURE 24. MYASTHENIA GRAVIS TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 25. MYASTHENIA GRAVIS TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 26. MYASTHENIA GRAVIS TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MYASTHENIA GRAVIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 100. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 101. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 102. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 103. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 104. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 105. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 106. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 107. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 108. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 109. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 114. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 115. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 116. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 117. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 118. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 119. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 120. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 121. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 122. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 123. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 186. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 187. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 188. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 189. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 190. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 191. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 192. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 193. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 194. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 195. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 200. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 201. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 202. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 203. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 204. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 205. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 206. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 207. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 208. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 209. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 228. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 229. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 230. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 231. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 232. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 233. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 234. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 235. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 236. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 237. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 242. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 243. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 244. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 245. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 246. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 247. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 248. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 249. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 250. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 251. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 298. DENMARK MYASTHENIA GRAVIS

Samples

Loading
LOADING...

Companies Mentioned

  • Alexion Pharmaceuticals, Inc.
  • argenx SE
  • UCB S.A.
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • CSL Limited
  • Roche Holding AG

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.11 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.76 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 230 Pages
  • Global
From
Myasthenia Gravis Treatment Market Report 2025 - Product Image

Myasthenia Gravis Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Myasthenia Gravis Treatment - Global Strategic Business Report - Product Image

Myasthenia Gravis Treatment - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Myasthenia Gravis Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Myasthenia Gravis Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 140 Pages
  • Global
From
Myasthenia Gravis Drugs - Global Strategic Business Report - Product Image

Myasthenia Gravis Drugs - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From

About the Myasthenia Gravis Drug Market

Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder that causes weakness in the skeletal muscles. MG is treated with a variety of drugs, including anticholinesterase drugs, immunosuppressants, and immunomodulators. Anticholinesterase drugs, such as pyridostigmine, are used to increase the availability of acetylcholine at the neuromuscular junction, thereby improving muscle strength. Immunosuppressants, such as azathioprine and cyclosporine, are used to reduce the production of antibodies that attack the neuromuscular junction. Immunomodulators, such as mycophenolate mofetil, are used to modulate the immune system and reduce the production of antibodies. The Myasthenia Gravis Drug market is a subset of the Central Nervous System Drugs market. It is composed of a variety of drugs used to treat MG, including anticholinesterase drugs, immunosuppressants, and immunomodulators. Companies in the Myasthenia Gravis Drug market include Merck, Pfizer, Novartis, GlaxoSmithKline, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.